Whole blood cells loaded with messenger RNA as an anti-tumor vaccine.

Adv Healthc Mater

Department of Chemical & Biomolecular Engineering, National University of Singapore, Singapore, 117576; Department of Biomedical Engineering, Duke University, Durham, NC, 27708, USA.

Published: June 2014

The use of a cell-based vaccine composed of autologous whole blood cells loaded with mRNA is described. Mice immunized with whole blood cells loaded with mRNA encoding antigen develop anti-tumor immunity comparable to DC-RNA immunization. This approach offers a simple and affordable alternative to RNA-based cellular therapy by circumventing complex, laborious and expensive ex vivo manipulations required for DC-based immunizations.

Download full-text PDF

Source
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4053491PMC
http://dx.doi.org/10.1002/adhm.201300512DOI Listing

Publication Analysis

Top Keywords

blood cells
12
cells loaded
12
loaded mrna
8
loaded messenger
4
messenger rna
4
rna anti-tumor
4
anti-tumor vaccine
4
vaccine cell-based
4
cell-based vaccine
4
vaccine composed
4

Similar Publications

Mycobacterium tuberculosis (M.tb) infection can lead to various outcomes, including active tuberculosis or latent tuberculosis infection (LTBI). Household contacts of TB cases have a high risk of acquiring LTBI.

View Article and Find Full Text PDF

Background: Segmentation models for clinical data experience severe performance degradation when trained on a single client from one domain and distributed to other clients from different domain. Federated Learning (FL) provides a solution by enabling multi-party collaborative learning without compromising the confidentiality of clients' private data.

Methods: In this paper, we propose a cross-domain FL method for Weakly Supervised Semantic Segmentation (FL-W3S) of white blood cells in microscopic images.

View Article and Find Full Text PDF

Inflammatory responses and lipid metabolism disorders are key components in the development of coronary artery disease and contribute to no-reflow after coronary intervention. This study aimed to investigate the association between the neutrophil to high-density lipoprotein ratio (NHR) and no-reflow phenomenon in ST-segment elevation myocardial infarction (STEMI) patients after primary percutaneous coronary intervention (PPCI). This study enrolled 288 patients with STEMI from September 1st, 2022 to February 29th, 2024, in the Zhengzhou Central Hospital Affiliated to Zhengzhou University.

View Article and Find Full Text PDF

T-helper 17 (Th17) cells significantly influence the onset and advancement of malignancies. This study endeavor focused on delineating molecular classifications and developing a prognostic signature grounded in Th17 cell differentiation-related genes (TCDRGs) using machine learning algorithms in head and neck squamous cell carcinoma (HNSCC). A consensus clustering approach was applied to The Cancer Genome Atlas-HNSCC cohort based on TCDRGs, followed by an examination of differential gene expression using the limma package.

View Article and Find Full Text PDF

Ultrasensitive Detection of Circulating Plasma Cells Using Surface-Enhanced Raman Spectroscopy and Machine Learning for Multiple Myeloma Monitoring.

Anal Chem

January 2025

Key Laboratory of OptoElectronic Science and Technology for Medicine of Ministry of Education, Fujian Provincial Key Laboratory of Photonics Technology, Fujian Normal University, Fuzhou, Fujian 350117, China.

Multiple myeloma is a hematologic malignancy characterized by the proliferation of abnormal plasma cells in the bone marrow. Despite therapeutic advancements, there remains a critical need for reliable, noninvasive methods to monitor multiple myeloma. Circulating plasma cells (CPCs) in peripheral blood are robust and independent prognostic markers, but their detection is challenging due to their low abundance.

View Article and Find Full Text PDF

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!